Clinical Trial Update: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety, tolerability, and potential efficacy markers for CHF 5074 in mild cognitive impairment and Alzheimer's disease, with a prolonge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• CHF 5074

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED